Type 1 Diabetes (Juvenile Diabetes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report View Sample

Published: October 31, 2022 Report Code: GDGMDHC22362IDB-ST

Select Item

Type 1 Diabetes Pipeline Drugs Market Report Overview

Type 1 diabetes (T1D) occurs when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, and irritability or unusual behavior.

The Type 1 Diabetes pipeline drugs market research report provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report reviews key players involved in therapeutic development for Type 1 Diabetes and features dormant and discontinued projects.

Key Targets Insulin Receptor, Interleukin 2 Receptor, Calcitonin Receptor, Islet Amyloid Polypeptide, Receptor Activity Modifying Protein 1, Receptor Activity Modifying Protein 2, Receptor Activity Modifying Protein 3, Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A, Glucagon Receptor, and Glucokinase
Key Mechanisms of Action Insulin Receptor Agonist, Interleukin 2 Receptor Agonist, Calcitonin Receptor Agonist, Receptor Activity Modifying Protein 1 Activator, Receptor Activity Modifying Protein 2 Activator, Receptor Activity Modifying Protein 3 Activator, Glucokinase Activator, Cannabinoid Receptor 1 Antagonist, Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Inhibitor, and Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAgonist
Key Routes of Administration Subcutaneous, Oral, Intravenous, Parenteral, Inhalational, Intramuscular, Intradermal, Intralymphatic, Nasal, and Topical
Key Molecule Types Recombinant Protein, Cell Therapy, Small Molecule, Monoclonal Antibody, Synthetic Peptide, Fusion Protein, Gene-Modified Cell Therapy, Gene Therapy, Vaccine, and Subunit Vaccine
Leading Companies Adocia SAS, Eli Lilly and Co, Novo Nordisk AS, Thermalin Inc, Biocon Ltd, Merck & Co Inc, Akston Biosciences Corp, Arecor Therapeutics Plc, CRISPR Therapeutics AG, and Diasome Pharmaceuticals Inc
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Type 1 Diabetes Pipeline Drugs Market Segmentation by Targets

Some of the key targets of the Type 1 Diabetes pipeline drugs market are Insulin Receptor, Interleukin 2 Receptor, Calcitonin Receptor, Islet Amyloid Polypeptide, Receptor Activity Modifying Protein 1, Receptor Activity Modifying Protein 2, Receptor Activity Modifying Protein 3, Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A, Glucagon Receptor, and Glucokinase. In 2022, insulin receptor was the most preferred target in the Type 1 diabetes pipeline drugs market.

Type 1 Diabetes Pipeline Drugs Market Analysis by Targets, 2022 (%)

Type 1 Diabetes Pipeline Drugs Market Analysis, by Targets

For more Type 1 Diabetes pipeline drugs market target insights, download a free report sample

Type 1 Diabetes Pipeline Drugs Market Segmentation by Mechanisms of Action

Some of the key mechanisms of action of the Type 1 Diabetes pipeline drugs market are Insulin Receptor Agonist, Interleukin 2 Receptor Agonist, Calcitonin Receptor Agonist, Receptor Activity Modifying Protein 1 Activator, Receptor Activity Modifying Protein 2 Activator, Receptor Activity Modifying Protein 3 Activator, Glucokinase Activator, Cannabinoid Receptor 1 Antagonist, Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Inhibitor, and Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAgonist. In 2022, the Insulin Receptor Agonist emerged as the largest adopted MoA for the Type 1 Diabetes Pipeline Drugs Market.

Type 1 Diabetes Pipeline Drugs Market Analysis by Mechanisms of Action, 2022 (%)

Type 1 Diabetes Pipeline Drugs Market Analysis, by Mechanisms of Action

For more mechanism of action insights into the Type 1 Diabetes pipeline drugs market, download a free report sample

Type 1 Diabetes Pipeline Drugs Market Segmentation by Routes of Administration

Some of the key routes of administration in the Type 1 Diabetes pipeline drugs market are subcutaneous, oral, intravenous, parenteral, inhalational, intramuscular, intradermal, intralymphatic, nasal, and topical. In 2022, the most adopted RoA in the Type 1 diabetes pipeline drugs market was subcutaneous.

Type 1 Diabetes Pipeline Drugs Market Analysis by Routes of Administration, 2022 (%)

Type 1 Diabetes Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the Type 1 Diabetes pipeline drugs market, download a free report sample

Type 1 Diabetes Pipeline Drugs Market Segmentation by Molecule Types

Some of the molecule types in the Type 1 Diabetes pipeline drugs market are recombinant protein, cell therapy, small molecule, monoclonal antibody, synthetic peptide, fusion protein, gene-modified cell therapy, gene therapy, vaccine, and subunit vaccine. In 2022, recombinant protein was the most preferred molecule for the Type 1 diabetes pipeline drugs market.

Type 1 Diabetes Pipeline Drugs Market Analysis by Molecule Types, 2022 (%)

Type 1 Diabetes Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the Type 1 Diabetes pipeline drugs market, download a free report sample

Type 1 Diabetes Pipeline Drugs Market - Competitive Landscape

Some of the leading companies in the Type 1 Diabetes pipeline drugs market are Adocia SAS, Eli Lilly and Co, Novo Nordisk AS, Thermalin Inc, Biocon Ltd, Merck & Co Inc, Akston Biosciences Corp, Arecor Therapeutics Plc, CRISPR Therapeutics AG, and Diasome Pharmaceuticals Inc. In 2022, Adocia SAS emerged as the market leader with the highest number of Type1 Diabetes pipeline drugs.

Type 1 Diabetes Pipeline Drugs Market Analysis by Companies, 2022 (%)

Type 1 Diabetes Pipeline Drugs Market Analysis, by Companies

To know more about the companies in the Type 1 Diabetes pipeline drugs market, download a free report sample

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).

  • Reviews of pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.

  • Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • Reviews of key companies involved in Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

  • Evaluation of Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.

  • All the dormant and discontinued pipeline projects.

  • Reviews of the latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Abata Therapeutics
Aditxt Inc
Adocia SAS
Aerami Therapeutics Inc
Ahead Therapeutics SL
Akston Biosciences Corp
Algiax Pharmaceuticals GmbH
Allele Biotechnology and Pharmaceuticals Inc
Alpine Immune Sciences Inc
Altheia Science SRL
ALTuCELL
Amarna Therapeutics BV
Amide Technologies Inc
AmideBio, LLC
Amogen Pharma Pvt Ltd
Amytrx Therapeutics Inc
Anokion SA
Aphios Corp
Apodemus AB
APT Therapeutics Inc
Aptamer Sciences Inc
Arecor Therapeutics Plc
Ariddad Therapeutics SL
Artery Therapeutics Inc
Asake Biotechnology LLC
AskGene Pharma Inc
AstraZeneca Plc
Asylia Therapeutics Inc
AVM Biotechnology LLC
Avotres Inc
Axxam SpA
Beijing Advaccine Biotechnology Company Ltd
Beta-Cell NV
Biocon Ltd
Biogenomics Ltd
BioLingus AG
Biomea Fusion Inc
Bioorg3.14 LLC
BioTherapeutics Inc
Biozeus Pharmaceutical SA
BirchBioMed Inc
Bol Pharma
Bopin (Shanghai) Biomedical Technology Co Ltd
Bristol-Myers Squibb Co
BTB Pharma AB
CAR-T (Shanghai) Biotechnology Co Ltd
Carlina Technologies SAS
Cell Source Inc
CellTrans Inc
Chongqing Chenan BioPharm Co Ltd
Code Biotherapeutics Inc
Coegin Pharma AS
Compugen Ltd
Cour Pharmaceuticals Development Co Inc
Creative Medical Technology Holdings Inc
CRISPR Therapeutics AG
Cue Biopharma Inc
Daewoong Pharmaceutical Co Ltd
Dendright Pty Ltd
Diabetology (Products) Ltd
Diamyd Medical AB
Diasome Pharmaceuticals Inc
DiaVacs Inc
Dompe Farmaceutici SpA
Dualogics Corp
Eli Lilly and Co
Endsulin Inc
Ensol Biosciences Inc
Enthera Srl
EpiVax Inc
Evotec SE
FasCure Therapeutics LLC
Felicitex Therapeutics Inc
Foshan Rexie Biotechnology Co Ltd
Fresh Tracks Therapeutics Inc
Gan & Lee Pharmaceuticals Co Ltd
Generex Biotechnology Corp
Genprex Inc
GentiBio Inc
Geropharm
Great Bay Bio Holdings Ltd
Gubra ApS
Gwoxi Stem Cell Applied Technology Co Ltd
Hanmi Pharmaceuticals Co Ltd
Housey Pharmaceutical Research Laboratories LLC
Hua Medicine Shanghai Ltd
Iltoo Pharma
Imagine Pharma LLC
ImCyse SA
Immunocore Holdings Plc
ImmunoMolecular Therapeutics LLC
Immunwork Inc
ImmusanT Inc
Imstem Biotechnology Inc
Innovimmune Biotherapeutics Inc
Inspira Therapeutics Inc
Intarcia Therapeutics Inc
Inversago Pharma Inc
iTolerance Inc
Jaguar Gene Therapy LLC
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Lianhuan Pharmaceutical Co Ltd
JN Biosciences LLC
Johnson & Johnson
Kadimastem Ltd
Kamada Pharmaceuticals
Kiniksa Pharmaceuticals Ltd
Kriya Therapeutics Inc
Kunming Yinnuo Medical Technology Co. Ltd.
L2 Diagnostics LLC
Landos Biopharma Inc
Lannett Co Inc
Larix Bioscience LLC
Laverock Therapeutics Ltd
Lexicon Pharmaceuticals Inc
Likarda LLC
MannKind Corp
Maruho Co Ltd
Medytox Inc
Melior Pharmaceuticals I Inc
Mercia Pharma Inc
Merck & Co Inc
MidaSol Therapeutics LP
Moderna Inc
Neovacs SA
Neurodon LLC
Neuromagen Pharma Ltd
NexImmune Inc
NextCell Pharma AB
NightHawk Biosciences Inc
Novartis AG
Novo Nordisk AS
OneVax LLC
Op-T-Mune Inc
Oramed Pharmaceuticals Inc
Orgenesis Inc
Orion BioScience Inc
Orizuru Therapeutics Inc
Otsuka Pharmaceutical Co Ltd
Panbela Therapeutics Inc
Pancryos AS
Panorama Researchama Research
Paras Biopharmaceuticals Finland Oy
Parvus Therapeutics Inc
Pfizer Inc
Phaim Pharma Ltd
PharmaCyte Biotech Inc
Pharmasum Therapeutics AS
PolTREG SA
Polus Inc
Precigen Inc
Prometheon Pharma LLC
Protheragen Inc
Protokinetix Inc
Protomer Technologies Inc
Provention Bio Inc
Purzer Pharmaceutical Co Ltd
Reata Pharmaceuticals Inc
Regenerative Medical Solutions Inc
REGiMMUNE Corp
Remd Biotherapeutics Inc
Remedium Bio Inc
reMYND NV
ReNeuron Group Plc
Renova Therapeutics Inc
Repertoire Immune Medicines Inc
RosVivo Therapeutics Inc
Rubius Therapeutics Inc
SAB Biotherapeutics Inc
Sahane Biotech Inc
Sana Biotechnology Inc
Sanofi
Sensulin LLC
Seraxis Inc
Serpin Pharma LLC
Shanghai Innogen Pharmaceutical Technology Co Ltd
Sihuan Pharmaceutical Holdings Group Ltd
Slate Bio Inc
Sonoma Biotherapeutics Inc
SQZ Biotechnologies Co
Stelis Biopharma Ltd
Suntec Medical (Taiwan) Inc
Surrozen Inc
SymbioCellTech LLC
Tetragenetics Inc
Theertha Biopharma Pvt Ltd
TherapyX Inc
Thermalin Inc
Throne Biotechnologies Inc
Tiziana Life Sciences Plc
Trailhead Biosystems Inc
Transgene Biotek Ltd
TwotoBiotech Ltd
Unicyte AG
Valin Technologies Ltd
Vanilloid Genetics Inc
Ventria Bioscience Inc
Veralox Therapeutics Inc
Vertex Pharmaceuticals Inc
ViaCyte Inc
ViCapsys Inc
Virtici LLC
vTv Therapeutics Inc
Wockhardt Ltd
Xeris Biopharma Holdings Inc
XL-protein GmbH
XOMA Corp
Yichang Hec Changjiang Pharmaceutical Co Ltd
Youngene Therapeutics Co Ltd
Zucara Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Type 1 Diabetes (Juvenile Diabetes) – Overview

Type 1 Diabetes (Juvenile Diabetes) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Type 1 Diabetes (Juvenile Diabetes) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Type 1 Diabetes (Juvenile Diabetes) – Companies Involved in Therapeutics Development

Type 1 Diabetes (Juvenile Diabetes) – Drug Profiles

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects

Type 1 Diabetes (Juvenile Diabetes) – Discontinued Products

Type 1 Diabetes (Juvenile Diabetes) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Frequently asked questions

  • What are the key targets of the Type 1 Diabetes pipeline drugs market?

    Some of the key targets of the Type 1 Diabetes pipeline drugs market are Insulin Receptor, Interleukin 2 Receptor, Calcitonin Receptor, Islet Amyloid Polypeptide, Receptor Activity Modifying Protein 1, Receptor Activity Modifying Protein 2, Receptor Activity Modifying Protein 3, Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A, Glucagon Receptor, and Glucokinase.

  • What are the key mechanisms of action of the Type 1 Diabetes pipeline drugs market?

    Some of the key mechanisms of action of the Type 1 Diabetes pipeline drugs market are Insulin Receptor Agonist, Interleukin 2 Receptor Agonist, Calcitonin Receptor Agonist, Receptor Activity Modifying Protein 1 Activator, Receptor Activity Modifying Protein 2 Activator, Receptor Activity Modifying Protein 3 Activator, Glucokinase Activator, Cannabinoid Receptor 1 Antagonist, Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Inhibitor, and Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAgonist.

  • What are the key routes of administration in the Type 1 Diabetes pipeline drugs market?

    Some of the key routes of administration in the Type 1 Diabetes pipeline drugs market are subcutaneous, oral, intravenous, parenteral, inhalational, intramuscular, intradermal, intralymphatic, nasal, and topical.

  • What are the key molecule types in the Type 1 Diabetes pipeline drugs market?

    Some of the molecule types in the Type 1 Diabetes pipeline drugs market are recombinant protein, cell therapy, small molecule, monoclonal antibody, synthetic peptide, fusion protein, gene-modified cell therapy, gene therapy, vaccine, and subunit vaccine.

  • Which are the leading companies in the Type 1 Diabetes pipeline drugs market?

    Some of the leading companies in the Type 1 Diabetes pipeline drugs market are Adocia SAS, Eli Lilly and Co, Novo Nordisk AS, Thermalin Inc, Biocon Ltd, Merck & Co Inc, Akston Biosciences Corp, Arecor Therapeutics Plc, CRISPR Therapeutics AG, and Diasome Pharmaceuticals Inc.

Type 1 Diabetes (Juvenile Diabetes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Type 1 Diabetes (Juvenile Diabetes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Metabolic Disorders reports
Pharmaceuticals
New
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Pharmaceuticals
New
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
$250 | November 2023
Pharmaceuticals
New
Net Present Value Model: Sarepta Therapeutics Inc's Patidistrogene bexoparvovec
$500 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Type 1 Diabetes (Juvenile Diabetes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Type 1 Diabetes (Juvenile Diabetes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more